ADAMTS8 Expression is a Potential Prognostic Biomarker for Postoperative Metastasis in Lymph Node-Negative Early-Stage Invasive Breast Carcinoma Patients

References

• Lei S, Zheng R, Zhang S, et al. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020. Cancer commun. 2021;41(11):1183–1194. doi:10.1002/cac2.12207
   PubMed Web of Science ®Google Scholar
• Koboldt DC, Fulton R, McLellan M, et al.Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. doi:10.1038/nature11412
   PubMed Web of Science ®Google Scholar
• Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. doi:10.1001/jama.2018.19323
   PubMed Web of Science ®Google Scholar
• Cserni G. Histological type and typing of breast carcinomas and the WHO classification changes over time. Pathologica. 2020;112(1):25–41. doi:10.32074/1591-951X-1-20
   PubMed Web of Science ®Google Scholar
• Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66. doi:10.1038/s41572-019-0111-2
   PubMed Web of Science ®Google Scholar
• Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134–1150. doi:10.1016/S0140-6736(16)31891-8
   PubMed Web of Science ®Google Scholar
• Shah C, Smith BD, Royce TJ. Balancing treatment deintensification strategies in early stage breast cancer. Int J Radiat Oncol Biol Phys. 2020;107(5):959–963. doi:10.1016/j.ijrobp.2020.04.037
   Web of Science ®Google Scholar
• Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. Int J Cancer. 2021;39(13):1485–1505. doi:10.1200/JCO.20.03399
   Web of Science ®Google Scholar
• Agostinetto E, Rediti M, Fimereli D, et al. HER2-low breast cancer: molecular characteristics and prognosis. Cancers. 2021;13(11):2824. doi:10.3390/cancers13112824
   PubMed Web of Science ®Google Scholar
• Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–1846. doi:10.1056/NEJMoa1701830
   PubMed Web of Science ®Google Scholar
• Chu QD, Hsieh MC, Lyons JM, Wu XC. 10-year survival after breast-conserving surgery compared with mastectomy in Louisiana women with early-stage breast cancer: a population-based study. J Am Coll Surg. 2021;232(4):607–621. doi:10.1016/j.jamcollsurg.2020.11.011
   Web of Science ®Google Scholar
• Choi HY, Park M, Seo M, Song E, Shin SY, Sohn YM. Preoperative axillary lymph node evaluation in breast cancer: current issues and literature review. Ultrasound Q. 2017;33(1):6–14. doi:10.1097/RUQ.0000000000000277
   Web of Science ®Google Scholar
• Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International expert consensus conference on the primary therapy of early breast cancer 2017. Ann Oncol. 2017;28(8):1700–1712. doi:10.1093/annonc/mdx308
   PubMed Web of Science ®Google Scholar
• Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American society of clinical oncology clinical practice guideline. Int J Cancer. 2016;34(10):1134–1150. doi:10.1200/JCO.2015.65.2289
   Web of Science ®Google Scholar
• Cardoso F, Van’t Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375(8):717–729. doi:10.1056/NEJMoa1602253
   PubMed Web of Science ®Google Scholar
• Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65. doi:10.1016/S1470-2045(09)70314-6
   PubMed Web of Science ®Google Scholar
• Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. Int J Cancer. 2009;27(8):1160–1167. doi:10.1200/JCO.2008.18.1370
   Web of Science ®Google Scholar
• Krop I, Ismaila N, Andre F, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American society of clinical oncology clinical practice guideline focused update. Int J Cancer. 2017;35(24):2838–2847. doi:10.1200/JCO.2017.74.0472
   Web of Science ®Google Scholar
• Kwa M, Makris A, Esteva FJ. Clinical utility of gene-expression signatures in early stage breast cancer. Nat Rev Clin Oncol. 2017;14(10):595–610. doi:10.1038/nrclinonc.2017.74
   PubMed Web of Science ®Google Scholar
• Zhu Y, Wang T, Tong Y, Chen X, Shen K. 21-gene recurrence assay associated with favorable metabolic profiles in HR-positive, HER2-negative early-stage breast cancer patients. Front Endocrinol. 2021;12:725161. doi:10.3389/fendo.2021.725161
   Web of Science ®Google Scholar
• Kok M, Koornstra RH, Mook S, et al. Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer. Breast. 2012;21(6):769–778. doi:10.1016/j.breast.2012.04.010
   Web of Science ®Google Scholar
• Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 2013;41(D1):D991–D995. doi:10.1093/nar/gks1193
   PubMed Web of Science ®Google Scholar
• Blum A, Wang P, Zenklusen JC. SnapShot: TCGA-analyzed tumors. Cell. 2018;173(2):530. doi:10.1016/j.cell.2018.03.059
   PubMed Web of Science ®Google Scholar
• Kern SE. Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res. 2012;72(23):6097–6101. doi:10.1158/0008-5472.CAN-12-3232
   PubMed Web of Science ®Google Scholar
• Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG. Reporting recommendations for tumor marker prognostic studies (REMARK): an Abridged explanation and elaboration. J Natl Cancer Inst. 2018;110(8):803–811. doi:10.1093/jnci/djy088
   PubMedGoogle Scholar
• Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57. doi:10.1038/nprot.2008.211
   PubMed Web of Science ®Google Scholar
• Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet. 2000;25(1):25–29. doi:10.1038/75556
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 2000;28(1):27–30. doi:10.1093/nar/28.1.27
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408. doi:10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar
• Vázquez F, Hastings G, Ortega MA, et al. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem. 1999;274(33):23349–23357. doi:10.1074/jbc.274.33.23349
   Web of Science ®Google Scholar
• Choi GC, Li J, Wang Y, et al. The metalloprotease ADAMTS8 displays antitumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylation. Mol Cancer Res. 2014;12(2):228–238. doi:10.1158/1541-7786.MCR-13-0195
   PubMed Web of Science ®Google Scholar
• Zhang X, Li D, Jia C, Cai H, Lv Z, Wu B. METTL14 promotes tumorigenesis by regulating lncRNA OIP5-AS1/miR-98/ADAMTS8 signaling in papillary thyroid cancer. Cell Death Dis. 2021;12(6):617. doi:10.1038/s41419-021-03891-6
   PubMed Web of Science ®Google Scholar
• Wu Z, Shi Y, Ren S, Ju Y, Hu Y, Wu J. ADAMTS8 inhibits progression of esophageal squamous cell carcinoma. DNA Cell Biol. 2020;39(12):2300–2307. doi:10.1089/dna.2020.6053
   Web of Science ®Google Scholar
• Li L, Yuan S, Zhao X, Luo T. ADAMTS8 is frequently down-regulated in colorectal cancer and functions as a tumor suppressor. Biochem Biophys Res Commun. 2020;524(3):663–671. doi:10.1016/j.bbrc.2020.01.020
   Web of Science ®Google Scholar
• Dunn JR, Reed JE, Du Plessis DG, et al. Expression of ADAMTS-8, a secreted protease with antiangiogenic properties, is downregulated in brain tumours. Br J Cancer. 2006;94(8):1186–1193.
   Web of Science ®Google Scholar
• Zhao X, Yang C, Wu J, Nan Y. ADAMTS8 targets ERK to suppress cell proliferation, invasion, and metastasis of hepatocellular carcinoma. Onco Targets Ther. 2018;11:7569–7578. doi:10.2147/OTT.S173360
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li J, He T, Ding J. Bioinformatics identified 17 immune genes as prognostic biomarkers for breast cancer: application study based on artificial intelligence algorithms. Front Oncol. 2020;10:330. doi:10.3389/fonc.2020.00330
   Web of Science ®Google Scholar
• Porter S, Span PN, Sweep FC, et al. ADAMTS8 and ADAMTS15 expression predicts survival in human breast carcinoma. Int J Cancer. 2006;118(5):1241–1247. doi:10.1002/ijc.21476
   PubMed Web of Science ®Google Scholar
• Zhang Y, Schnabel CA, Schroeder BE, et al. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res. 2013;19(15):4196–4205. doi:10.1158/1078-0432.CCR-13-0804
   PubMed Web of Science ®Google Scholar
• Pu M, Messer K, Davies SR, et al. Research-based PAM50 signature and long-term breast cancer survival. Breast Cancer Res Treat. 2020;179(1):197–206. doi:10.1007/s10549-019-05446-y
   Web of Science ®Google Scholar
• Almstedt K, Mendoza S, Otto M, et al. EndoPredict(®) in early hormone receptor-positive, HER2-negative breast cancer. Breast Cancer Res Treat. 2020;182(1):137–146. doi:10.1007/s10549-020-05688-1
   Web of Science ®Google Scholar
• Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014;14(6):430–439. doi:10.1038/nrc3726
   PubMed Web of Science ®Google Scholar
• Gkretsi V, Stylianopoulos T. Cell adhesion and matrix stiffness: coordinating cancer cell invasion and metastasis. Front Oncol. 2018;8:145. doi:10.3389/fonc.2018.00145
   PubMed Web of Science ®Google Scholar
• Aoki M, Fujishita T. Oncogenic roles of the PI3K/AKT/mTOR axis. Curr Top Microbiol Immunol. 2017;407:153–189. doi:10.1007/82_2017_6
   PubMed Web of Science ®Google Scholar
• Carragher NO, Frame MC. Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. Trends Cell Biol. 2004;14(5):241–249. doi:10.1016/j.tcb.2004.03.011
   PubMed Web of Science ®Google Scholar
• Burridge K. Focal adhesions: a personal perspective on a half century of progress. FEBS J. 2017;284(20):3355–3361. doi:10.1111/febs.14195
   PubMed Web of Science ®Google Scholar
• Lamalice L, Le Boeuf F, Huot J. Endothelial cell migration during angiogenesis. Circ Res. 2007;100(6):782–794. doi:10.1161/01.RES.0000259593.07661.1e
   PubMed Web of Science ®Google Scholar
• Ma Q, Reiter RJ, Chen Y. Role of melatonin in controlling angiogenesis under physiological and pathological conditions. Angiogenesis. 2020;23(2):91–104. doi:10.1007/s10456-019-09689-7
   PubMed Web of Science ®Google Scholar